Literature DB >> 32300622

Dataset of cognitive behavioral intervention for persons living with HIV in China: A randomized pilot trial.

Shuyu Han1, Yan Hu1, Zheng Zhu1, Bei Wu2.   

Abstract

Globally, persons living with HIV (PLWH) are vulnerable to depressive and anxious symptoms [1]. Cognitive behavioural therapy (CBT) is one of the first-line mental health treatment strategies for PLWH [2-3]. However, structured and systematic cognitive behavioural intervention (CBI) is rare for PLWH in China. This data article presents the raw data of a parallel two-arm randomized controlled trial investigating the preliminary effects of CBI on depression, anxiety, medication adherence, quality of life, and CD4 lymphocyte counts for PLWH in China. Twenty PLWH who aged ≥18, were undergoing antiretroviral therapy (ART), and scored the Patient Health Questionnaire-4 (PHQ-4) ≥2 were recruited face-to-face and randomly assigned to groups based on computerized random number generation. Intervention participants received a tailored group-based 10-week-long CBI. Control participants only took laboratory tests and received free ART medication. The data includes demographic variables, exposure variables and outcomes. The outcomes were repeated-measured at baseline (T0), after the intervention (T1), and after 6 months of follow-up (T2). We assessed depression and anxiety via the Hospital Anxiety and Depression Scale (HADS), quality of life via the WHOQOL-HIV BREF, medication adherence via self-report adherence, the visual analog scale (VAS) and the medication possession ratio (MPR). CD4 lymphocyte counts were available on participants' medical records. The main manuscript of this dataset is "cognitive behavioral intervention for persons living with HIV in China: a randomized pilot trial" (Han et al., submitted for publication) [4].
© 2020 The Author(s).

Entities:  

Keywords:  AIDS; Anxiety; Cognitive behavioural therapy; Depression; HIV; Medication adherence; Randomized controlled trial

Year:  2020        PMID: 32300622      PMCID: PMC7153287          DOI: 10.1016/j.dib.2020.105459

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications table

Value of the data

The data can provide better knowledge for researchers and policymakers to evaluate the prospects of CBT for PLWH care in China. The data can provide reference for future research study design in the field of PLWH mental health care in China. The data can provide evidence for nursing practice of providing CBI for PLWH in China. The data may influence the model of mental health services for PLWH in China in the long term.

Data description

Tables 1–6 contain all the raw data of the randomized controlled trial. Baseline demographic information is shown in Tables 1 and 2. Tables 3–5 present outcomes data at T0, T1 and T2 respectively. Table 6 presents the attendance rates of the intervention group.
Table 1

Demographic variables of the study.

IDAgeGenderHousehold registerRaceEducationReligionEmployment statusMarital status
1441116212
2261214112
3361115212
4481215141
5351216212
6321115112
7421226212
8431212112
9551116111
10291215211
11271115112
12381115112
13301116112
14351215112
15371215212
16371214111
17241215212
18251215222
19351215112
20451114212

Note: Patients 1–10:intervention group; Patients 11–20:control group.

Gender: 1 = Male; 2 = Female.

Household register: 1 = Shanghai; 2 = Non-Shanghai.

Race: 1 = Han; 2 = Minority.

Education: 1 = Primary school or less; 2 = Junior high school; 3 = Senior high school; 4 = College; 5 = University; 6 = Master or higher.

Religion: 1 = No; 2 = Yes.

Employment status: 1 = Employed; 2 = Unemployed; 3 = Sick leave; 4 = Retired.

Marital status: 1 = Married; 2 = Single.

Table 6

Exposure variables (Attendance rates).

IDSessions
Attendance
12345678910
110
29
37
47
56
69
71
81
94
106
Table 2

PHQ-4 and HIV-related variables.

IDPHQ-4Transmission modeCD4 lymphocyte count(/µL)HIV-RNAYears of HIV diagnosisYears of receiving ART
141376011
231370011
361266011
442197022
551253066
651356066
7101768087
841443087
951409098
1063372044
1123433011
1241509072
1341339022
1451549033
1521295033
16101436044
1731539044
1851481044
1991265055
2044449055

Note: Patients 1–10: intervention group; Patients 11–20: control group.

Transmission mode: 1 = Homosexual behavior; 2 = Heterosexual behavior; 3 = Unknown; 4 = Other.

HIV-RNA: 0 = Undetectable; 1 = Detectable.

Years of HIV diagnosis: how many years has the participants been diagnosed with HIV infection?

Years of receiving ART: how many years has the participants been taking ART?

Table 3

Outcomes at baseline (T0).

IDAnxietyDepressionNegative emotionPhysical domainPsychological domainIndependence domainSocial domainEnvironment domainSpirituality domainQuality of lifeVASSelf-report adherenceMPRMPR (binary)CD4(/µL)
113102318211915381713610021.032376
211112216191517301411910021.062370
3172037118121221138310020.992266
41511261721161836201379020.992197
51410241117111428181049511.222253
6131528141412132316979811.012356
7221436121617142112989511.172768
81515301414141228141028511.132443
917122916191614311411810011.012409
101311241415151426151059811.002372
1110132318171617341812810021.002433
1214112514161515341711910020.992509
131511261519171830161249010.911339
1415102517181312311711610021.382549
151310231517141631181189521.142295
16231639121211916127810020.921436
171411251515121126191059811.172539
181316291315141229171058011.002481
19171431131411132513959510.972265
201311242016141331201239510.921449

Note: Patients 1–10: intervention group; Patients 11–20: control group.

Anxiety: range from 7 to 28.

Depression: range from 7 to 28.

Negative emotion = Anxiety+Depression, range from 14 to 56.

Physical domain: range from 4 to 20.

Psychological domain: range 5 to 25.

Independence domain: range from 4 to 20.

Social domain: range from 4 to 20.

Environment domain: range from 8 to 40.

Spirituality domain: range from 4 to 20.

Quality of life = Physical domain+Psychological domain+Independence domain+Social domain+Environment domain+Spirituality domain+2 general items, range from 31 to 155.

VAS: visual analogue scale, range from 0 to 100.

Self-report adherence:1 = modest,2 = good.

MPR: medication possession ratio = time interval between two prescriptions/90.

MPR(binary):1 = modest(MPR<0.95),2 = good(MPR≥0.95).

Table 5

Outcomes at the 6-month follow-up (T2).

IDAnxietyDepressionNegative emotionPhysical domainPsychological domainIndependence domainSocial domainEnvironment domainSpirituality domainQuality of lifeVASSelf-report adherenceMPRMPR (binary)CD4 (/µL)
115142918191814341712810020.931532
21515301415121125129410021.292498
31620361011121122148510020.992479
477141924181737201459020.992488
597161620151529191209021.12506
61514291516141426161079020.992396
72010301719201333111209911.432908
81516311115121125159510021.962430
979161721191635191359021.022501
1012820131515122017989021.062512
1111122317211616321912910021.072455
1412112316211715311712510021.452585
1514102418211615301712510021.182286
16181836131213101915879020.941393
17141125121511112315938021.32481
181414281419161330191195010.931541
191512271415141227141029520.992293
2014112520171515311612210010.921359
Demographic variables of the study. Note: Patients 1–10:intervention group; Patients 11–20:control group. Gender: 1 = Male; 2 = Female. Household register: 1 = Shanghai; 2 = Non-Shanghai. Race: 1 = Han; 2 = Minority. Education: 1 = Primary school or less; 2 = Junior high school; 3 = Senior high school; 4 = College; 5 = University; 6 = Master or higher. Religion: 1 = No; 2 = Yes. Employment status: 1 = Employed; 2 = Unemployed; 3 = Sick leave; 4 = Retired. Marital status: 1 = Married; 2 = Single. PHQ-4 and HIV-related variables. Note: Patients 1–10: intervention group; Patients 11–20: control group. Transmission mode: 1 = Homosexual behavior; 2 = Heterosexual behavior; 3 = Unknown; 4 = Other. HIV-RNA: 0 = Undetectable; 1 = Detectable. Years of HIV diagnosis: how many years has the participants been diagnosed with HIV infection? Years of receiving ART: how many years has the participants been taking ART? Outcomes at baseline (T0). Note: Patients 1–10: intervention group; Patients 11–20: control group. Anxiety: range from 7 to 28. Depression: range from 7 to 28. Negative emotion = Anxiety+Depression, range from 14 to 56. Physical domain: range from 4 to 20. Psychological domain: range 5 to 25. Independence domain: range from 4 to 20. Social domain: range from 4 to 20. Environment domain: range from 8 to 40. Spirituality domain: range from 4 to 20. Quality of life = Physical domain+Psychological domain+Independence domain+Social domain+Environment domain+Spirituality domain+2 general items, range from 31 to 155. VAS: visual analogue scale, range from 0 to 100. Self-report adherence:1 = modest,2 = good. MPR: medication possession ratio = time interval between two prescriptions/90. MPR(binary):1 = modest(MPR<0.95),2 = good(MPR≥0.95). Outcomes after intervention (T1). Outcomes at the 6-month follow-up (T2). Exposure variables (Attendance rates). Among the 20 participants, all were males, with a mean age of 36.15 years old. Most of the participants (60%) did not have a Shanghai household registry, which means that they were migrants from other areas. The majority of the participants (95%) were of Han ethnicity. Most of them had a high educational level, with 80% of them having a bachelor's degree or higher. Approximately half of the participants had a religious affiliation. Most of them were employed (90%). Only 4 participants were married (20%) (Table 1). Of the total sample, the participants showed an average PHQ-4 score of 5.00, an average year of diagnosis of 4.20 years, and average years of receiving ART of 3.80 years. Half of the participants (50%) had CD4 lymphocyte counts of more than 400/µL, with an average count of 405/µL. All had the latest undetectable virus load (100%). Most of them (80%) were infected with HIV because of homosexual behavior (Table 2). Among all the outcomes, all are continuous variables except the self-report adherence and the MPR. After a 10-week intervention, one participant in the control group refused to continue follow-up (Table 4). Another participant in the control group was unable to be contacted after the 6-month follow-up (Table 5). No one dropped out of the intervention group. The sample retention rate was 90%.
Table 4

Outcomes after intervention (T1).

IDAnxietyDepressionNegative emotionPhysical domainPsychological domainIndependence domainSocial domainEnvironment domainSpirituality domainQuality of lifeVASSelf-report adherenceMPRMPR (binary)CD4 (/µL)
11181918211915351713310021.12665
212142617181613271010710020.941340
31713301213121222138910020.992318
4791620241416391814010020.992488
5781518211616322013110020.811488
61314271415141326141029021.032386
71412261722191429151239920.992690
8181533121514122811979521.272333
91414281619171433161239020.992453
10131023141614122099110020.982512
1112142619191718341412910010.992462
1213102316191814321412210021.112511
1413102317201613311712210020.962444
151412261819151730191269020.851297
16201535121413112016919021.072436
171514291114141125149410021.142473
181512271119161428161116010.851510
19171431141414122412969011.012351
201410241917161530191249711.172307
According to our sign-in record, within the intervention group, one participant attended ten sessions; two participants attended nine sessions; two participants attended seven sessions; two participants attended six sessions; one participant attended four sessions; two participants attended one session. The overall attendance rate was 60% (Table 6).

Experimental design, materials, and methods

A randomized controlled trial was conducted to examine the preliminary effects of group CBI on depression (primary outcome), anxiety, quality of life, medication adherence, and CD4 lymphocyte count (secondary outcomes). This study was approved by the Research Ethical Committee of the School of Nursing, Fudan University (IRB#TYSA2016-3–1), and Shanghai Public Health Center Affiliated with Fudan University (2019-S036-02). It was also registered with the Chinese Clinical Trial Registry (ChiCTR1900024256). Participants were eligible if they met the following inclusion criteria: ①Participants who had been diagnosed with HIV-1 infection; ②more than 18 years old; ③receiving anti-retroviral treatment (ART); ④the Patient Health Questionnaire-4 (PHQ-4) score≥2. Participants were excluded if they ①could not participate in our study because of severe comorbidities or cognitive impairment and ②were taking part in other HIV-related research projects at the same time. Participants were assigned in the control or the intervention group randomly. We used the WPS EXCEL software to generate the random sequence and sorted the random number by size. After the eligible participants signed the informed consent form, they were asked to open an envelope that contained the information about the assigned group. The data collection staff was blinded. We designed the “1 + 2 + 10” strategy in the intervention group, which means one nurse, two voluntary assistant intervention providers with psychological background, and ten participants in the CBT group. Table 7 summarizes the content of the intervention sessions.
Table 7

Content of intervention sessions.

SessionDidactic componentsActivity/Topic
1An explanation for group goals, physiological effects of stressIce-breaking activity, collection of questions and expectations
2Conception and interpretation of CBTWhat dose HIV infection mean to me?
3Definition and practice skills of mindfulnessWhy am I a gay?
4Identification of cognitive distortions and automatic thoughtsIntimate relationships
5Rational thought replacementHow to minimize the impact of medication on life?
6Coping skills trainingWhat will I do when physicians reject me?
7Assertiveness trainingCareer development
8Emotion managementFake marriage and surrogacy
9Identification of social supportHIV confidentiality and notification
10SummaryLook into the mirror
Content of intervention sessions.
SubjectNursing and Health Professions
Specific subject areaMental Health Nursing, AIDS Care
Type of dataTables
How data were acquiredQuestionnaires include a standardized demographic questionnaire, a 4-item Patient Health Questionnaire-4 (PHQ-4) for screening participants’ depression and anxiety, a 14-item Hospital Anxiety and Depression Scale (HADS), a 31-item WHOQOL-HIV BREF, a 2-item self-report adherence questionnaire, and numerical 0–100 visual analogue scale (VAS). We asked two questions for self-reported medication adherence. ①In the past month, did you miss taking medication or mistakenly take medication? ②In the past month, did you delay or take medication ahead of time by more than 2 h? If a participant answered “no” to both questions, we defined him/her as having good adherence; otherwise, the participant belonged to modest adherence category. The questionnaire is provided as a supplementary file.
Every participant was receiving free antiretroviral therapy (ART) under the Chinese National Policies of “Four Frees and One Care for HIV/AIDS” [1], [2], [3], [4], [5]. They received routine follow-up every 3 months in the Shanghai Public Health Center Affiliated with Fudan University outpatient center, which included taking routine blood tests, urine tests, and receiving free ART medication. Their visit records and laboratory test results could be acquired from their medical records. After completing all the follow-ups, we checked every participant's latest four visit records to calculated their medication possession ratio (MPR) at T0, T1 and T2. The CD4 lymphocyte count was also acquired from medical records. Approved by the Research Ethical Committee both in School of Nursing, Fudan University and Shanghai Public Health Center Affiliated with Fudan University, we were allowed to login the in the archives system and check medical records.
Data formatRaw data
Parameters for data collectionThe parameters included depression, anxiety, quality of life, medication adherence, CD4 lymphocyte count.
Description of data collectionWe invited two nurses in the outpatient department to help us collect data. Neither of them participated in the intervention, so the data collection was blinded. The data collectors distributed paper questionnaires or let participants scan a QR code to fill out the questionnaire online. Data collectors checked the paper questionnaire on the spot and gave the questionnaire back if the patients had missed any questions. Online questionnaires could be submitted only after answering all the questions. Medical records were checked on the computers in the hospital to obtain patients’ follow-up intervals and CD4 lymphocyte counts.
Data source locationShanghai Public Health Center Affiliated with Fudan University, Shanghai, China
Data accessibilityAll the data for this randomized controlled trial are accessible in this data article.
  4 in total

1.  Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis.

Authors:  Sepide Rezaei; Saba Ahmadi; Jeiran Rahmati; Hossein Hosseinifard; Afsaneh Dehnad; Aidin Aryankhesal; Hosein Shabaninejad; Shabnam Ghasemyani; Samira Alihosseini; Nicola Luigi Bragazzi; Samira Raoofi; Zahra Mansour Kiaee; Ahmad Ghashghaee
Journal:  BMJ Support Palliat Care       Date:  2019-09-19       Impact factor: 3.568

2.  Evidence-based clinical practice guidelines for managing depression in persons living with HIV.

Authors:  Michael V Relf; Shelly Eisbach; Kayj Nash Okine; Terry Ward
Journal:  J Assoc Nurses AIDS Care       Date:  2013 Jan-Feb       Impact factor: 1.354

3.  Anxiety symptoms in HIV-infected individuals.

Authors:  Jeanne K Kemppainen; Sally MacKain; Darcel Reyes
Journal:  J Assoc Nurses AIDS Care       Date:  2013 Jan-Feb       Impact factor: 1.354

4.  Antiretroviral Therapy Initiation Following Policy Changes: Observations From China.

Authors:  Li Li; Guoping Ji; Chunqing Lin; Li-Jung Liang; Chiao-Wen Lan
Journal:  Asia Pac J Public Health       Date:  2016-05-23       Impact factor: 1.399

  4 in total
  1 in total

Review 1.  Global Systematic Review of Common Mental Health Disorders in Adults Living with HIV.

Authors:  Jacqueline Hoare; Tatum Sevenoaks; Bulelwa Mtukushe; Taryn Williams; Sarah Heany; Nicole Phillips
Journal:  Curr HIV/AIDS Rep       Date:  2021-11-18       Impact factor: 5.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.